During the past decade, SCRI - Tennessee Oncology conducted 35 clinical trials. In the 10-year time frame, 35 clinical trials started and 16 clinical trials were completed, i.e. on average, 45.7% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 11 clinical trials were completed. i.e. 64.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "SCRI - Tennessee Oncology" #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "EMD Serono Research & Development Institute, Inc." with 5 trials sponsored, "Genentech, Inc." with 5 trials sponsored, "Takeda" with 2 trials sponsored and "AnHeart Therapeutics Inc." with 2 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "SCRI - Tennessee Oncology" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 5 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "AbbVie (prior sponsor, Abbott)" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Daiichi Sankyo Co., Ltd." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "SCRI - Tennessee Oncology" are "Solid Tumors" (4 trials), "Multiple Myeloma" (3 trials), "Breast Cancer" (2 trials), "Leukemia, Myeloid, Acute" (2 trials) and "Melanoma" (2 trials). Many other conditions were trialed in "SCRI - Tennessee Oncology" in a lesser frequency.

Most popular intervention types in "SCRI - Tennessee Oncology" are "Drug" (39 trials), "Other" (2 trials), "Biological" (1 trials), "Device" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (6 trials), "Gemcitabine" (5 trials), "Placebo" (4 trials), "Avelumab" (3 trials) and "Cisplatin" (3 trials). Other intervention names were less common.

The vast majority of trials in "SCRI - Tennessee Oncology" are 39 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "SCRI - Tennessee Oncology". undefined are not yet recruiting, 12 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in SCRI - Tennessee Oncology, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in SCRI - Tennessee Oncology, 12 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".